Solitaire-Iv: Results Of A Phase 3 Iv To Oral Trial In Adults With Community-Acquired Bacterial Pneumonia Comparing Solithromycin To Moxifloxacin

被引：0
|
作者：
File, T. M., Jr. [1 ]
Rewerska, B. [2 ]
Tanaseanu, C. M. [3 ]
Mihailovic-Vucinic, V. [4 ]
Gonong, J. R. [5 ]
Jamieson, B. D. [6 ]
Taylor, D. [6 ]
Sheets, A. [6 ]
Keedy, K. [6 ]
Oldach, D. W. [6 ]
Fernandes, P. [6 ]
机构：
[1] Summa Hlth Syst, Akron, OH USA
[2] Diamond Clin, Krakow, Poland
[3] St Pantelimon Emergency Clin Hosp, Bucharest, Romania
[4] Clin Ctr Serbia, Belgrade, Serbia
[5] Lung Ctr Philippines, Manila, Philippines
[6] Cempra Inc, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2116
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial
    Jardim, JR
    Rico, G
    de la Roza, C
    Obispo, E
    Urueta, J
    Wolff, M
    Miravitlles, M
    ARCHIVOS DE BRONCONEUMOLOGIA, 2003, 39 (09): : 387 - 393
  • [22] An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxidav with or without clarithromycin in the treatment of community-acquired pneumonia
    Drummond, MF
    Becker, DL
    Hux, M
    Chancellor, JVM
    Duprat-Lomon, I
    Kubin, R
    Sagnier, PP
    CHEST, 2003, 124 (02) : 526 - 535
  • [23] Safety and efficacy of sequential IV To PO moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial IV Therapy
    Katz, E
    Larsen, LS
    Fogarty, CM
    Hamed, K
    Song, J
    Choudhri, S
    JOURNAL OF EMERGENCY MEDICINE, 2004, 27 (04): : 395 - 405
  • [24] Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia
    Oldach, David
    Clark, Kay
    Schranz, Jennifer
    Das, Anita
    Craft, J. Carl
    Scott, Drusilla
    Jamieson, Brian D.
    Fernandes, Prabhavathi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2526 - 2534
  • [25] OUTCOMES IN TREATMENT OF EUROPEAN (EU) PATIENTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) COMPARING DELAFLOXACIN (DLX) AND MOXIFLOXACIN (MOX)
    Zinzi, D.
    Horcajada, J. P.
    Madej, A.
    Lawrence, L.
    Cammarata, S.
    CHEST, 2020, 157 (06) : 75A - 75A
  • [26] A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia
    Morganroth, J
    DiMarco, JP
    Anzueto, A
    Niederman, MS
    Choudhri, SJ
    CHEST, 2005, 128 (05) : 3398 - 3406
  • [27] Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
    Ramirez, Julio
    Deck, Daniel H.
    Eckburg, Paul B.
    Curran, Marla
    Das, Anita F.
    Kirsch, Courtney
    Manley, Amy
    Tzanis, Evan
    McGovern, Paul C.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06):
  • [28] A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial
    Lloyd, A.
    Holman, A.
    Evers, T.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1279 - 1284
  • [29] Pivot trial: A multicentre randomised equivalence trial to compare oral and IV treatment for community acquired pneumonia in children
    Atkinson, M
    Lakhanpaul, M
    Smyth, A
    Vyas, H
    Weston, V
    Sithole, J
    Halliday, K
    Sammons, H
    Walton, L
    Guntupalli, N
    Crane, J
    Ninan, T
    Morjaria, A
    Owen, V
    Stephenson, T
    THORAX, 2004, 59 (01) : 21 - 21
  • [30] A cost-minimization analysis comparing moxifloxacin versus levofloxacin and ceftriaxone for the treatment of patients hospitalized with Community-Acquired Pneumonia: Results from the MOTIV trial
    Lloyd, A. C.
    Holman, A. J.
    VALUE IN HEALTH, 2007, 10 (06) : A307 - A307
12345